1629O - Prognostic factors of tumour cellularity in image-guided biopsies: Results from a prospective molecular triage trial (MOSCATO)

Date 27 September 2014
Event ESMO 2014
Session Biomarkers and tumour heterogeneity
Topics Staging Procedures (clinical staging)
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Vania Tacher
Citation Annals of Oncology (2014) 25 (suppl_4): iv564-iv573. 10.1093/annonc/mdu359
Authors V. Tacher1, M. Le Deley2, J. Soria3, A. Hollebecque4, F. Deschamps1, A. Hakime1, E. Ileana4, P. Vielh5, C. Massard6, A. Behnoush4, C. Charpy4, D. Gajda2, A. Celebic4, M. Ngocamus7, S. Gouissem4, V. Cartier1, M. Barral4, V. Koubi-Pick5, L. Lacroix4, T. De Baere1
  • 1Interventional Radiology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2Clinical Epidemiology And Biostatistics, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3Sitep, Institut Gustave Roussy, 94800 - villejuif/FR
  • 4Medical Oncology, Institut Gustave Roussy, Villejuif/FR
  • 5Histo-cyto Pathology, Institut Gustave Roussy, Villejuif/FR
  • 6Medical Oncology, Gustave-Roussy, 94805 - Villejuif/FR
  • 7Service Des Opérations De Recherche Clinique, Institut Gustave Roussy, Villejuif/FR



MOSCATO (molecular-screening for cancer treatment optimization) is a prospective molecular triage trial based on on-purpose tumour biopsies to perform molecular portraits. We aimed at identifying factors that predict a high cellularity in image-guided tumour biopsy.


The percentage of tumour cells was evaluated on each biopsy sample. The primary endpoint was the maximum percentage of tumour cells across the different samples. All CT-scan images were centrally reviewed. Non-parametric tests were used to compare the distribution of the maximum percentage of tumour cells, between subsets of patients (pts). Paired samples (central vs. peripheral) were compared when multiple samples were obtained.


Among the 460 enrolled pts from November 2011 to March 2014, 335 pts (73%) had an image-guided needle biopsy of the primary tumour (n=39, 12%) or a metastatic lesion (n=296, 88%). Biopsies were performed on liver (n=127, 38%), lung (n=71, 21%), lymph nodes (n=71, 21%), bone (n=11, 3%), and other tumour sites (n=55, 16%). Sixteen pts (5.7%) experienced a complication: pneumothorax in 8 pts treated medically, and haemorrhage in 8 pts requiring embolisation in 3 cases. The median percentage of tumour cells was 50% (Q1-Q3, 30-70%). Age, gender, on-going chemotherapy, target origin (primitive vs. metastasis), number of lesions in the biopsied organ, target lesion size, tumour growth rate, presence of necrosis and size of the needle were not statistically related to a high cellularity (P<0.05). Compared to liver, lung or lymph nodes biopsies, cellularity was significantly lower in bone and higher in other sites (P=.002). Cellularity significantly increased with increasing number of samples done and was higher in biopsies guided by contrast enhanced ultrasound (P<.001). In pts with paired samples, cellularity in central samples was lower than in peripheral samples in 83, equal in 66 and higher in 82 cases.


The majority of tumour biopsies provided molecular screening efficiency with a low rate of complications. Imaging modality used to guide to the biopsy, multiple samples, peripheral and central, and the chosen organ were the prognostic factors of cellularity.


All authors have declared no conflicts of interest.